viewProactive Group

Investor Update: Faron Pharma's YODA study confirms Traumakine suspicions

Top stories from the Proactive Investors UK newsroom.

The much awaited feasibility study on Asiamet’s (LON:ARS) BKM project’s out this morning revealing an initial 9 year mine life producing up to 25,000 tonnes of copper cathode a year. The Post Tax NPV’s come in at $133.5 million.

Immotion Group PLC (LON:IMMO) has signed a three-year deal with Survios, a virtual reality (VR) studio backed by media firm MGM, for content to install in its new VR Arena.

Faron Pharmaceuticals Oy (LON:FARN) has released the final results of the YODA study into its interferon-beta drug Traumakine.  A phase III clinical trial – called “INTEREST” - on patients with a condition called acute respiratory distress syndrome didn’t yield the anticipated results, and the YODA study was instigated to find out why.

Frontier IP Group PLC’s (LON:FIPP) portfolio firm Exscientia has entered a drug discovery collaboration with Shanghai-based biotech GT Apeiron Therapeutics. As part of the partnership Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programme

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Immotion plans fundraising following deal with Las Vegas resort

Immotion Group (LON:IMMO) has raised gross proceeds of £2.85mln from an 'oversubscribed' fundraising to accelerate its growth plans, and revealed it has inked a revenue-sharing deal with the MGM Mandalay Bay resort and casino in Las Vegas. CEO Martin Higginson tells Proactive London what the...

1 day, 2 hours ago

2 min read